Spectral Medical Inc  

(Public, TSE:EDT)   Watch this stock  
Find more results for TSE:SDI
+0.030 (4.17%)
Oct 2 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.72 - 0.75
52 week 0.26 - 1.18
Open 0.72
Vol / Avg. 0.00/91,540.00
Mkt cap 143.04M
P/E     -
Div/yield     -
EPS -0.05
Shares 190.71M
Beta 1.61
Inst. own     -
Nov 11, 2015
Q3 2015 Spectral Medical Inc Earnings Release (Estimated) Add to calendar
Aug 14, 2015
Q2 2015 Spectral Medical Inc Earnings Release
Aug 11, 2015
Spectral Medical Inc at Wedbush PacGrow Healthcare Conference

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -289.24% -320.24%
Operating margin -292.18% -342.81%
EBITD margin - -334.08%
Return on average assets -84.64% -89.13%
Return on average equity -111.18% -130.78%
Employees 19 -
CDP Score - -


135 the West Mall Unit 2
+1-416-6263233 (Phone)
+1-416-6267383 (Fax)

Website links


Spectral Medical Inc. (Spectral), formerly Spectral Diagnostics Inc., is a therapeutic development company. Spectral is focused on the development and commercialization of a treatment for severe sepsis and septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents. The Company's only clinical development program is for PMX. Spectral is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. The Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators.

Officers and directors

Anthony P. Bihl III Chairman of the Board
Paul M. Walker M.D., Ph.D. President, Chief Executive Officer, Director
Anthony Businskas Chief Financial Officer, Executive Vice President, Corporate Secretary
Gualitiero Guadagni Vice President - Sales and Marketing
Debra M. Foster RN Vice President - Clinical Development
William Charles Stevens Director
Guillermo A. Herrera Independent Director